Myelomax is a preclinical CRO specializing in Multiple Myeloma target candidate testing and evaluation services for pharmaceutical and biotech companies, and research organizations who are working to advance therapies for Multiple Myeloma.

Unique collection of 38 Human Myeloma Cell Lines

The most representative of the heterogeneity of Multiple Myeloma

Unrivalled advice

Choose those Human Myeloma Cell Lines that are most appropriate for your study

Fully tailored studies

Each study is custom designed to meet your investigational needs

Short turnaround times

For prompt and cost-effective target candidate evaluation
cro-multiple-myeloma-myelomax

Unlike other generalist or non-specialist preclinical contract research organsinions, Myelomax is the only preclinical CRO wholly dedicated to Multiple Myeloma. This means we are well placed to provide unique expertise to pharmaceutical and biotech companies, and research institutions who wish to evaluate in vitro and in vivo the clinical potential of target candidates for Multiple Myeloma.

Myelomax

6

years

Spin-off created in 2010

1600

assay tests

Conducted over 1600 assay tests to date

34

molecules evaluated

Evaluated over 34 molecules

Why this focus on Multiple Myeloma?

Each year worldwide more than 115,000 people are newly diagnosed with Multiple Myeloma, a type of blood cancer that develops from plasma cells in bone marrow. Recent advances in treatment mean that survival rates have significantly improved to between 5 and 9 years. However with time patients relapse as treatments fail to work over the long term meaning that for most patients the disease remains incurable. Over 220 people still die each day from Multiple Myeloma – the equivalent of 1 to 2% of all cancer related deaths in Western countries.

Myelomax helps pharmaceutical and biotech companies, and academic researchers in the battle to bring more effective drugs to market.

Get a quote for in-vitro and in-vivo Multiple Myeloma testing and evaluation services.